Couldn't find what you looking for?

TRY OUR SEARCH!

Table of Contents

Testosterone is being touted as a possible therapeutic tool in the fight against obesity and metabolic diseases. But is there any scientific evidence for such a novel approach? There is, in fact, tons of evidence!

As opposed to popular belief, numerous scientific studies hint towards the usefulness of testosterone as a therapeutic tool.

Some medical conditions which definitely warrant testosterone supplementation – either short-term or long-term are – amongst others – hypogonadism, obesity, diabetes and cardiovascular diseases.

Listed below are some medical conditions in which testosterone supplementation, as is reported by researchers, may prove to be definitely helpful. Please note that although medical literature abounds in such proofs, just a few of those studies have been cited here:

  • Testosterone supplementation may offer protection from cardiovascular disease in men. In a paper published in 2010, Ginzburg and his colleagues (Ginzburg et al., 2010) showed that testosterone either alone or in combination with lipid-lowering drugs like statins  causes a significant decrease in total cholesterol, low-density lipoprotein cholesterol (LDL or the ‘bad cholesterol’) and total triglycerides levels in the blood. Testosterone therapy may, therefore, translate into protection against cardiovascular disease.
  • An androgen deficiency (as in hypogonadism) has been shown to be inherently connected to increased incidence of metabolic diseases (Traish, Guay, Feeley, & Saad, 2009)
  • Obesity is associated with hormonal imbalances including testosterone deficiency (Seidell, Bjorntorp, Sjostrom, Kvist, & Sannerstedt, 1990). Testosterone therapy, not surprisingly, helps reduce to fat deposits in obese men.
  • Androgen deprivation therapy (used for prostate cancer) causes a significant increase in body fat and decrease in lean mass (muscles and bones) (Smith, Lee, & Nathan, 2006; Smith et al., 2002; Chen et al., 2002), suggesting again that testosterone may have a role to play in improving body composition and fighting obesity
  • As opposed to previous thought, low testosterone levels may be responsible for causing pancreatic cancer (von, Pina, Perez, Tavares, & Barros, 2004)

Alleged Adverse Effects of Testosterone Supplementation

Testosterone supplementation has been shown by studies to be generally safe, especially  in combination with lifestyle changes – regular exercise and partaking of a wholesome, health diet (Ginzburg et al., 2010).

Adverse effects, even when they do occur have a very low incidence rate – a dismal 1.3% .

Some adverse effects that testosterone is believed to cause are prostate cancer, breast cancer (which can indeed affect men) and cardiovascular disease.

Testosterone and Cancer

Up until recently, a physician’s biggest fear of prescribing testosterone was the alleged risk of stimulating uncontrolled growth in the prostatic cells – leading to cancer.

Recent findings, however, tend to suggest otherwise; testosterone supplementation may not be associated with prostate cancer after all (Raynaud, 2006; Morgentaler, 2006; Raynaud, 2009). In fact, as state earlier, low levels of testosterone may increase the risk of prostatic cancer (von et al., 2004).

Use of testosterone in women (when added to hormone replacement therapy in post-menopausal women) was also thought to increase the risk of (breast) cancer.  However, there is severe lack of evidence for such suggestions as well (Bitzer, Kenemans, & Mueck, 2008). Inconsistent clinical data and previously conduced, flawed trials may be to blame for such thinking on the part of physicians.

Conclusion

In a nutshell, there seems to be enough scientific evidence to suggest that testosterone supplementation* may be both effective and safe in fighting metabolic disease, improving quality of life and general well-being.

Additionally, future therapeutic will (and should), in all probability, include testosterone as an important therapeutic tool to tackle human obesity as well.

*please note that testosterone or anabolic-androgenic steroids (AAS) used for performance enhancement is sports is another topic and does not fall within the purview of this article

  • Anderson, F. H., Francis, R. M., & Faulkner, K. (1996). Androgen supplementation in eugonadal men with osteoporosis-effects of 6 months of treatment on bone mineral density and cardiovascular risk factors. Bone, 18, 171-177
  • Bitzer, J., Kenemans, P., & Mueck, A. O. (2008). Breast cancer risk in postmenopausal women using testosterone in combination with hormone replacement therapy. Maturitas, 59, 209-218
  • Chen, Z., Maricic, M., Nguyen, P., Ahmann, F. R., Bruhn, R., & Dalkin, B. L. (2002). Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma. Cancer, 95, 2136-2144
  • Ginzburg, E., Klimas, N., Parvus, C., Life, J., Willix, R., Barber, M. J. et al. (2010). Long-term Safety of Testosterone and Growth Hormone Supplementation: A Retrospective Study of Metabolic, Cardiovascular, and Oncologic Outcomes. J Clin Med Res., 2, 159-166
  • Ginzburg, E., Klimas, N., Parvus, C., Life, J., Willix, R., Barber, M. J. et al. (2010). Long-term Safety of Testosterone and Growth Hormone Supplementation: A Retrospective Study of Metabolic, Cardiovascular, and Oncologic Outcomes. J Clin Med Res., 2, 159-166
  • Kaplan, S. A., Meehan, A. G., & Shah, A. (2006). The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men? J Urol, 176, 1524-1527
  • Kohn, F. M. (2006). Testosterone and body functions. Aging Male, 9, 183-188
  • Kupelian, V., Hayes, F. J., Link, C. L., Rosen, R., & McKinlay, J. B. (2008). Inverse association of testosterone and the metabolic syndrome in men is consistent across race and ethnic groups. J Clin Endocrinol.Metab, 93, 3403-3410
  • Lebrasseur, N. K., Lajevardi, N., Miciek, R., Mazer, N., Storer, T. W., & Bhasin, S. (2009). Effects of testosterone therapy on muscle performance and physical function in older men with mobility limitations (The TOM Trial): design and methods. Contemp.Clin Trials, 30, 133-140
  • Mohr, B. A., Bhasin, S., Link, C. L., O'Donnell, A. B., & McKinlay, J. B. (2006). The effect of changes in adiposity on testosterone levels in older men: longitudinal results from the Massachusetts Male Aging Study. Eur J Endocrinol., 155, 443-452
  • Morgentaler, A. (2006). Testosterone replacement therapy and prostate risks: where's the beef? Can.J Urol, 13 Suppl 1, 40-43
  • Perleth, M. (2007). [Testosterone--a "fountain of youth" for ageing men? Brief assessment of the efficacy and safety of androgen substitution in healthy men]. Z.Arztl.Fortbild.Qualitatssich., 101, 487-497
  • Raynaud, J. P. (2006). Prostate cancer risk in testosterone-treated men. J Steroid Biochem.Mol.Biol., 102, 261-266
  • Raynaud, J. P. (2009). Testosterone deficiency syndrome: treatment and cancer risk. J Steroid Biochem.Mol.Biol., 114, 96-105
  • Rodriguez, A., Muller, D. C., Metter, E. J., Maggio, M., Harman, S. M., Blackman, M. R. et al. (2007). Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol.Metab, 92, 3568-3572
  • Seidell, J. C., Bjorntorp, P., Sjostrom, L., Kvist, H., & Sannerstedt, R. (1990). Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism, 39, 897-901
  • Smith, M. R., Finkelstein, J. S., McGovern, F. J., Zietman, A. L., Fallon, M. A., Schoenfeld, D. A. et al. (2002). Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol.Metab, 87, 599-603
  • Smith, M. R., Lee, H., & Nathan, D. M. (2006). Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol.Metab, 91, 1305-1308
  • Svartberg, J., von, M. D., Sundsfjord, J., & Jorde, R. (2004). Waist circumference and testosterone levels in community dwelling men. The Tromso study. Eur J Epidemiol., 19, 657-663
  • Traish, A. M., Guay, A., Feeley, R., & Saad, F. (2009). The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J Androl, 30, 10-22
  • von, H. P., Pina, F., Perez, A., Tavares, M., & Barros, H. (2004). Visceral fat accumulation as a risk factor for prostate cancer. Obes Res., 12, 1930-1935
  • Wittert, G. A., Chapman, I. M., Haren, M. T., Mackintosh, S., Coates, P., & Morley, J. E. (2003). Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol.A Biol.Sci.Med Sci., 58, 618-625
  • Zang, H. & Davis, S. R. (2008). Androgen replacement therapy in androgen-deficient women with hypopituitarism. Drugs, 68, 2085-2093
  • Photo courtesy of Mark Probst by Flickr : www.flickr.com/photos/schani/14508174/
  • Photo courtesy of Schlonz by Wikimedia Commons : commons.wikimedia.org/wiki/File:Depo-testosterone_200_mg_ml.jpg